Sign In
Buy AMPH
$18.12
-0.330 (-1.79%)
At Close: Jun 03, 2026
Needham Thinks Zynerba Pharmaceuticals’ Stock is Going to Recover
09:38am, Thursday, 16'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on Zynerba Pharmaceuticals (
ZYNE
–
Research Report
) today and set a price target of
$16.00
. The company’s shares closed last Wednesday at
BioCryst (BCRX) Gets a Hold Rating from Needham
09:27am, Thursday, 16'th Apr 2020
In a report released today, Serge Belanger from Needham maintained a Hold rating on BioCryst (BCRX). The company's shares closed last Wednesday at $2.70.
Needham Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
09:27am, Thursday, 16'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company's shares
Needham Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
09:27am, Thursday, 16'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on KalVista Pharmaceuticals (
KALV
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Wednesday at
Liquidia Technologies (LQDA) Receives a Buy from Needham
09:00pm, Wednesday, 15'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA) today and set a price target of $30.00. The company's shares closed
Liquidia Technologies (LQDA) Receives a Buy from Needham
09:00pm, Wednesday, 15'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price
Needham Keeps Their Buy Rating on Heron Therapeutics (HRTX)
10:38am, Wednesday, 15'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics (HRTX) today and set a price target of $44.00. The company's shares closed
Needham Keeps Their Buy Rating on Heron Therapeutics (HRTX)
10:38am, Wednesday, 15'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on Heron Therapeutics (
HRTX
–
Research Report
) today and set a price target of
$44.00
. The company’s shares closed last Tuesday at $14.85.
Flexion Therapeutics (FLXN) Receives a Buy from Needham
10:29am, Wednesday, 15'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $36.00. The company's shares closed
Needham Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
10:29am, Wednesday, 15'th Apr 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Revance Therapeutics (RVNC), with a price target of $36.00. The
Needham Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
10:29am, Wednesday, 15'th Apr 2020
In a report released today,
Serge Belanger
from Needham maintained a
Buy
rating on Revance Therapeutics (
RVNC
–
Research Report
), with a price target of
$36.00
. The company’s shares closed last
Alliancebernstein L.P. Purchases 1,400 Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
08:28am, Wednesday, 15'th Apr 2020
Alliancebernstein L.P. boosted its position in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 1.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 109,340 shares of the company
Needham Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)
04:36pm, Tuesday, 14'th Apr 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI), with a price target of $18.00. The company's
Needham Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)
04:36pm, Tuesday, 14'th Apr 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report),
Amphastar Pharma's President bids adieu
11:44am, Tuesday, 14'th Apr 2020
Amphastar Pharmaceuticals (NASDAQ:AMPH) announces that Mr. Jason B. Shandell has stepped down as President, General Counsel, and member of the Board of Directors, effective April 10. Dr. Jack Y. Zha
